JumpCan Pharmaceutical (stock code: 600566) and Akeso (stock code: 9926.HK) have officially signed a collaboration agreement. JumpCan Pharmaceutical obtains exclusive commercialization rights for the Class 1 innovative drug Ebronucimab Injection (Yixining) in the People's Republic of China (excluding the Hong Kong and Macao Special Administrative Regions and Taiwan, China), jointly opening a new chapter in the commercialization of innovative cardiovascular drugs.
Ebronucimab Injection (Yixining) is a novel PCSK9 monoclonal antibody drug independently developed by Akeso. It received marketing approval in September 2024 for the treatment of primary hypercholesterolemia and mixed dyslipidemia, including heterozygous familial hypercholesterolemia (HeFH) and hypercholesterolemia in patients also suffering from atherosclerotic cardiovascular disease. Yixining has been included in the 2025 edition of the National Reimbursement Drug List (NRDL) and is cited in both the Chinese Expert Consensus on Comprehensive Management of Lipid-Related Cardiovascular Risk (2025 Edition) and the Guideline for Rational Drug Use and Comprehensive Management of Dyslipidemia in County-Level Regions (2025 Edition).
This collaboration is not only an important milestone in JumpCan Pharmaceutical's business expansion, but also a key breakthrough in the company's strategic deployment in the cardiovascular therapeutic area — marking a solid step forward in JumpCan Pharmaceutical's path toward innovative drug commercialization. As a PCSK9 monoclonal antibody drug independently developed in China, Yixining provides a new option for the clinical treatment of hypercholesterolemia and the long-term management of cardiovascular risk.
Cao Wei, General Manager of JumpCan Pharmaceutical Group, stated: "We are honored to enter into a strategic collaboration with Akeso. This partnership not only represents an important breakthrough in JumpCan Pharmaceutical's commercialization strategy, but also a profound embodiment of the company's medium- and long-term development strategy to expand therapeutic areas in line with clinical needs — reflecting our firm commitment to continuously providing high-quality, innovative treatment solutions for patients. Currently, atherosclerotic cardiovascular disease has become the leading health threat to China's population, and lipid management is key to preventing related cardiovascular events. This collaboration will help promote the widespread adoption of innovative lipid management solutions and jointly safeguard the cardiovascular health of the nation, ensuring that cutting-edge medical achievements benefit more patients and contributing to improving the health and wellbeing of the entire population."
Dr. Xia Yu, Founder, Chairman, President, and CEO of Akeso, stated: "We are delighted to see the combination of Akeso and JumpCan Pharmaceutical's strengths — a convergence of China's independent pharmaceutical innovation and superior industrial resources, which will powerfully drive the advancement of cardiovascular health for the Chinese people and contribute to building a Healthy China. Relevant data show that China has 110 million hypercholesterolemia patients, representing a vast unmet clinical need. This collaboration will fully leverage JumpCan Pharmaceutical's extensive market network and professional commercialization capabilities, enabling more patients to benefit from the excellent clinical value of Akeso's innovative PCSK9 monoclonal antibody, achieve better disease control, and improve their quality of life."
About Ebronucimab Injection (Yixining):
Ebronucimab Injection (Yixining) is a novel PCSK9 monoclonal antibody drug independently developed by Akeso, indicated for the treatment of primary hypercholesterolemia and mixed dyslipidemia, including heterozygous familial hypercholesterolemia (HeFH) and hypercholesterolemia in patients also suffering from atherosclerotic cardiovascular disease.
Yixining specifically binds to PCSK9 and blocks its interaction with LDL-R, restoring LDL-R expression levels to enhance the clearance of LDL-C from plasma. Previous research has demonstrated that treatment with PCSK9 monoclonal antibodies on the background of statin therapy can significantly reduce cholesterol levels and lower the risk of heart attack and stroke. Phase III clinical studies showed that Yixining demonstrates excellent clinical efficacy in patients across very high-risk, extremely high-risk, high-risk, and moderate-to-low-risk stratifications, regardless of baseline LDL-C levels.
About Akeso:
Akeso (9926.HK) is a leading enterprise integrating the research, development, manufacturing, and commercialization of first-in-class or best-in-class innovative biologics globally. Always centering on patients and guided by clinical value, Akeso has built its unique end-to-end Akeso comprehensive new drug R&D platform and established an innovation system centered on Tetrabody bispecific antibody development technology, antibody-drug conjugate (ADC) technology, siRNA/mRNA technology, and cell therapy technology — along with an internationally standardized GMP manufacturing system and an advanced commercialization system — making it a globally competitive biopharmaceutical innovation company.
Since its establishment, the company has developed more than 50 innovative drug candidates for treating major diseases including tumors, autoimmune, inflammatory, and metabolic diseases. Twenty-six candidates have entered clinical stages (including 15 bispecific/multispecific antibodies and bispecific ADCs), seven new drugs are commercially marketed, and marketing applications for two drugs covering four indications are under regulatory review. In September 2024, the company's independently developed Yixining (Ebronucimab, PCSK9) received approval for two indications in the treatment of hypercholesterolemia, becoming its first approved product outside the oncology field.
About JumpCan Pharmaceutical:
JumpCan Pharmaceutical (600566.SH) is a national-level high-tech enterprise and national technology innovation demonstration enterprise integrating product R&D, manufacturing, and commercial operations. It ranks among the Top 100 Chinese Pharmaceutical Industrial Enterprises and the Top 10 Most Valuable Listed Pharmaceutical Companies for Investment in China. Our main business covers pharmaceuticals and cosmetics & toiletries, focusing on core therapeutic areas including respiratory, pediatrics, gastroenterology, women's health, dermatology, and cardiovascular diseases. We hold multiple nationally exclusive varieties and dosage forms with a leading market position.
Guided by the purpose of "Build a Joyful and Vibrant Life Together", we are oriented toward clinical medication needs and everyday health demands, providing accessible and diversified solutions to help improve people's lives and give back value to society.